AUA BPH

Provides evidence‑based recommendations for evaluating and treating lower urinary tract symptoms caused by benign prostatic hyperplasia.

Incompl Void
Not at all0Less than 1 time in 5+1Less than half the time+2About half the time+3More than half the time+4Almost always+5
<2 hr
Not at all0Less than 1 time in 5+1Less than half the time+2About half the time+3More than half the time+4Almost always+5
Stop/Restart
Not at all0Less than 1 time in 5+1Less than half the time+2About half the time+3More than half the time+4Almost always+5
Diff to Delay
Not at all0Less than 1 time in 5+1Less than half the time+2About half the time+3More than half the time+4Almost always+5
Weak Stream
Not at all0Less than 1 time in 5+1Less than half the time+2About half the time+3More than half the time+4Almost always+5
Must Push/Strain
Not at all0Less than 1 time in 5+1Less than half the time+2About half the time+3More than half the time+4Almost always+5
During Sleep
None01 time+12 times+23 times+34 times+45 times+5

Indications for Use

Used for men ≥45 with bothersome LUTS attributed to BPH after excluding other causes; guides evaluation, need for medical therapy, and thresholds for referral or surgery. Clinical utility is to standardize symptom scoring (IPSS), identify candidates for α‑blockers or 5‑ARIs, and determine when complications (retention, infections, stones, hematuria, renal insufficiency) warrant surgical management (AUA Guideline 1).

Insights & Cautions

Start with symptom scoring and objective measures (IPSS, prostate size, flow rate), but avoid overreliance because these tools do not predict progression or treatment response well (AUA Guideline 2021 1 [Level I evidence]). Key cautions: limited validation across diverse populations; no ability to estimate risk of acute urinary retention or incidental cancer; and should not substitute for clinical assessment, urinalysis, or shared decision-making.